146 related articles for article (PubMed ID: 20048709)
1. Novel adjuvants for B cell immune responses.
Loré K; Karlsson Hedestam GB
Curr Opin HIV AIDS; 2009 Sep; 4(5):441-6. PubMed ID: 20048709
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory combinations: designing the next generation of vaccine adjuvants.
Kornbluth RS; Stone GW
J Leukoc Biol; 2006 Nov; 80(5):1084-102. PubMed ID: 16931603
[TBL] [Abstract][Full Text] [Related]
3. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
Cagigi A; Nilsson A; De Milito A; Chiodi F
Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
5. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
[TBL] [Abstract][Full Text] [Related]
6. The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants.
Sasaki S; Tsuji T; Asakura Y; Fukushima J; Okuda K
Anticancer Res; 1998; 18(5D):3907-15. PubMed ID: 9854503
[TBL] [Abstract][Full Text] [Related]
7. The science of adjuvants.
Kwissa M; Kasturi SP; Pulendran B
Expert Rev Vaccines; 2007 Oct; 6(5):673-84. PubMed ID: 17931149
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects of adjuvants on B cells.
Vollmer J; Bellert H
Methods Mol Biol; 2010; 626():131-48. PubMed ID: 20099126
[TBL] [Abstract][Full Text] [Related]
9. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
10. Modulation of HIV-1 immunity by adjuvants.
Moody MA
Curr Opin HIV AIDS; 2014 May; 9(3):242-9. PubMed ID: 24670321
[TBL] [Abstract][Full Text] [Related]
11. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
[TBL] [Abstract][Full Text] [Related]
12. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
[TBL] [Abstract][Full Text] [Related]
13. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
14. Challenges for structure-based HIV vaccine design.
Schief WR; Ban YE; Stamatatos L
Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
16. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
[TBL] [Abstract][Full Text] [Related]
17. Current world literature.
Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137
[No Abstract] [Full Text] [Related]
18. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
19. Translating innate immunity into immunological memory: implications for vaccine development.
Pulendran B; Ahmed R
Cell; 2006 Feb; 124(4):849-63. PubMed ID: 16497593
[TBL] [Abstract][Full Text] [Related]
20. The perfect mix: recent progress in adjuvant research.
Guy B
Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
